Discovery/RB
and/CC
Evaluation/NN
of/IN
Polymorphisms/NNS
in/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
Promoter/NN
Regions/NNS
for/IN
Risk/NN
of/IN
Korean/JJ
Lung/NN
Cancer/NN
./.
====================
AKT/NN
is/VBZ
a/DT
signal/NN
transduction/NN
protein/NN
that/WDT
plays/VBZ
a/DT
central/JJ
role/NN
in/IN
the/DT
tumorigenesis/NN
./.
====================
There/EX
are/VBP
3/CD
mammalian/JJ
isoforms/NNS
of/IN
this/DT
serine/threonine/NN
protein/NN
kinase-AKT1/NN
,/,
AKT2/NN
,/,
and/CC
AKT3-showing/JJ
a/DT
broad/JJ
tissue/NN
distribution/NN
./.
====================
We/PRP
first/RB
discovered/JJ
2/CD
novel/JJ
polymorphisms/NNS
(/(
AKT2/NN
-9826/CD
C/G/NN
and/CC
AKT3/NN
-811/CD
A/G/NN
)/)
,/,
and/CC
we/PRP
confirmed/VBD
6/CD
known/VBN
polymorphisms/NNS
(/(
AKT2/NN
-9473/CD
C/T/NN
,/,
AKT2/NN
-9151/CD
C/T/NN
,/,
AKT2/NN
-9025/CD
C/T/NN
,/,
AKT2/NN
-8618G/A/NN
,/,
AKT3/NN
-675/CD
A/-/JJ
,/,
and/CC
AKT3/NN
-244/CD
C/T/NN
)/)
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
promoter/NN
region/NN
in/IN
24/CD
blood/NN
samples/NNS
of/IN
Korean/JJ
lung/NN
cancer/NN
patients/NNS
using/VBG
direct/JJ
sequencing/NN
./.
====================
To/TO
evaluate/VB
the/DT
role/NN
of/IN
AKT2/NN
and/CC
AKT3/NN
polymorphisms/NNS
in/IN
the/DT
risk/NN
of/IN
Korean/JJ
lung/NN
cancer/NN
,/,
genotypes/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
polymorphisms/NNS
(/(
AKT2/NN
-9826/CD
C/G/NN
,/,
AKT2/NN
-9473/CD
C/T/NN
,/,
AKT2/NN
-9151/CD
C/T/NN
,/,
AKT2/NN
-9025/CD
C/T/NN
,/,
AKT2/NN
-8618G/A/NN
,/,
and/CC
AKT3/NN
-675/CD
A/-/JJ
)/)
were/VBD
determined/VBN
in/IN
360/CD
lung/NN
cancer/NN
patients/NNS
and/CC
360/CD
normal/JJ
controls/NNS
./.
====================
Statistical/JJ
analyses/NNS
revealed/VBD
that/IN
the/DT
genotypes/NNS
and/CC
haplotypes/NNS
in/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
promoter/NN
regions/NNS
were/VBD
not/RB
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
These/DT
results/NNS
suggest/VBP
that/IN
polymorphisms/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
promoter/NN
regions/NNS
do/VBP
not/RB
contribute/VB
to/TO
the/DT
genetic/JJ
susceptibility/NN
to/TO
lung/NN
cancer/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
Lung/NN
cancer/NN
has/VBZ
been/VBN
the/DT
leading/VBG
cause/VBP
of/IN
cancer-related/JJ
deaths/NNS
in/IN
Korea/NN
,/,
and/CC
its/PRP$
incidence/NN
continues/NNS
to/TO
rise/VB
[/(
1/CD
]/)
./.
====================
Despite/IN
therapeutic/JJ
advances/NNS
,/,
the/DT
overall/JJ
5-year/JJ
survival/NN
remains/VBZ
only/RB
15/CD
%/NN
[/(
2/CD
]/)
./.
====================
Lung/NN
cancer/NN
is/VBZ
a/DT
multicellular/JJ
and/CC
multistage/JJ
process/NN
that/WDT
involves/VBZ
a/DT
number/NN
of/IN
genetic/JJ
changes/NNS
in/IN
oncogenes/NNS
and/CC
tumor/NN
suppressor/NN
genes/NNS
./.
====================
Nevertheless/RB
,/,
the/DT
prognosis/NN
of/IN
lung/NN
cancer/NN
has/VBZ
remained/VBN
poor/JJ
despite/IN
innovations/NNS
in/IN
diagnostic/JJ
testing/NN
and/CC
surgical/JJ
technique/NN
and/CC
the/DT
development/NN
of/IN
new/JJ
chemotherapeutic/JJ
agents/NNS
./.
====================
Recently/RB
introduced/VBN
targeted/VBN
agents/NNS
show/VBP
different/JJ
responses/NNS
according/VBG
to/TO
histological/JJ
subtype/NN
,/,
and/CC
the/DT
efficiency/NN
of/IN
treatment/NN
modalities/VBZ
for/IN
lung/NN
cancer/NN
depends/VBZ
on/IN
the/DT
time/NN
of/IN
diagnosis/NN
[/(
3/CD
]/)
./.
====================
Therefore/RB
,/,
there/EX
is/VBZ
a/DT
great/JJ
need/NN
for/IN
rapid/JJ
and/CC
efficient/JJ
early/JJ
detection/NN
methods/NNS
./.
====================
For/IN
developing/VBG
improved/VBN
molecular/JJ
biomarkers/NNS
for/IN
the/DT
early/JJ
detection/NN
and/CC
prediction/NN
of/IN
response/NN
to/TO
chemotherapy/NN
,/,
it/PRP
is/VBZ
important/JJ
to/TO
identify/VB
genetic/JJ
alterations/NNS
specific/JJ
to/TO
each/DT
subtype/NN
of/IN
lung/NN
cancer/NN
./.
====================
Single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
represent/VBP
an/DT
important/JJ
class/NN
of/IN
genetic/JJ
variations/NNS
and/CC
affect/VB
an/DT
individual/JJ
's/POS
susceptibility/NN
to/TO
disease/NN
in/IN
certain/JJ
circumstances/NNS
[/(
4-6/CD
]/)
./.
====================
Activation/NN
of/IN
the/DT
intracellular/JJ
survival/NN
signal/NN
transduction/NN
protein/NN
AKT/NN
,/,
known/VBN
as/IN
protein/NN
kinase/NN
B/NN
,/,
has/VBZ
been/VBN
proposed/VBN
as/IN
a/DT
central/JJ
signaling/NN
event/NN
in/IN
carcinogenesis/NN
and/CC
has/VBZ
been/VBN
shown/VBN
in/IN
experimental/JJ
models/NNS
to/TO
confer/VB
resistance/NN
to/TO
chemotherapy/NN
and/CC
radiation/NN
[/(
7/CD
,/,
8/CD
]/)
./.
====================
AKT/NN
is/VBZ
activated/VBN
by/IN
phosphatidylinositol/NN
3/CD
phosphates/NNS
,/,
the/DT
products/NNS
of/IN
phosphoinositide/NN
3-kinase/NN
(/(
PI3K/NN
)/)
activity/NN
[/(
9/CD
]/)
./.
====================
Additionally/RB
,/,
AKT/NN
activity/NN
is/VBZ
commonly/RB
dysregulated/VBN
in/IN
a/DT
variety/NN
of/IN
human/JJ
tumors/NNS
because/IN
of/IN
frequent/JJ
inactivation/NN
of/IN
the/DT
PTEN/NN
tumor/NN
suppressor/NN
gene/NN
,/,
which/WDT
negatively/RB
regulates/VBZ
phosphatidylinositol/NN
3/CD
phosphate/NN
levels/NNS
,/,
and/CC
alterations/NNS
of/IN
this/DT
gene/NN
have/VBP
been/VBN
identified/VBN
in/IN
various/JJ
cancers/NNS
,/,
including/VBG
lung/NN
cancer/NN
[/(
10/CD
,/,
11/CD
]/)
./.
====================
To/TO
date/NN
,/,
3/CD
human/JJ
isoforms/NNS
of/IN
AKT/NN
have/VBP
been/VBN
identified/VBN
,/,
AKT1/NN
,/,
AKT2/NN
,/,
and/CC
AKT3/NN
,/,
which/WDT
are/VBP
expressed/VBN
in/IN
lung/NN
,/,
breast/NN
,/,
colon/NN
,/,
and/CC
prostate/NN
tumor/NN
tissues/NNS
[/(
12/CD
]/)
./.
====================
Somatic/JJ
mutations/NNS
of/IN
AKTs/NNS
have/VBP
been/VBN
reported/VBN
in/IN
endometrial/JJ
carcinomas/NNS
,/,
hypoglycemia/NN
,/,
and/CC
breast/NN
cancer/NN
[/(
13/CD
,/,
14/CD
]/)
./.
====================
However/RB
,/,
somatic/JJ
mutations/NNS
in/IN
AKT/NN
families/NNS
are/VBP
rare/JJ
in/IN
lung/NN
cancer/NN
[/(
15/CD
,/,
16/CD
]/)
./.
====================
Previously/RB
,/,
it/PRP
was/VBD
reported/VBN
that/IN
an/DT
AKT1/NN
polymorphism/NN
was/VBD
not/RB
associated/VBN
with/IN
schizophrenia/NN
[/(
17/CD
,/,
18/CD
]/)
./.
====================
AKT1/NN
and/CC
AKT2/NN
polymorphisms/NNS
have/VBP
been/VBN
reported/VBN
to/TO
be/VB
related/JJ
to/TO
survival/NN
of/IN
esophageal/JJ
cancer/NN
[/(
19/CD
]/)
,/,
and/CC
it/PRP
was/VBD
reported/VBN
that/IN
an/DT
AKT1/NN
polymorphism/NN
was/VBD
associated/VBN
with/IN
survival/NN
in/IN
surgically/RB
resected/JJ
non-small/JJ
cell/NN
lung/NN
cancer/NN
[/(
20/CD
]/)
./.
====================
However/RB
,/,
the/DT
association/NN
between/IN
AKT2/NN
and/CC
AKT3/NN
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
has/VBZ
not/RB
yet/RB
been/VBN
clarified/VBN
./.
====================
This/DT
study/NN
discovered/VBD
polymorphisms/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
promoter/NN
regions/NNS
and/CC
their/PRP$
relation/NN
with/IN
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Study/NN
subjects/NNS
====================
Between/IN
August/NNP
2001/CD
and/CC
November/NN
2010/CD
,/,
blood/NN
samples/NNS
were/VBD
collected/VBN
from/IN
720/CD
subjects/NNS
,/,
including/VBG
360/CD
lung/NN
cancer/NN
patients/NNS
and/CC
360/CD
normal/JJ
controls/NNS
without/IN
cancer/NN
./.
====================
Lung/NN
cancer/NN
patients/NNS
were/VBD
recruited/VBN
from/IN
the/DT
patient/NN
pool/NN
at/IN
the/DT
Genomic/JJ
Research/NN
Center/JJ
for/IN
Lung/NN
and/CC
Breast/Ovarian/JJ
Cancer/NN
,/,
and/CC
control/JJ
subjects/NNS
were/VBD
randomly/RB
selected/VBN
from/IN
a/DT
pool/NN
of/IN
healthy/JJ
volunteers/NNS
who/WP
had/VBD
visited/VBN
the/DT
Cardiovascular/JJ
Genome/NN
Center/JJ
and/CC
Genomic/JJ
Research/NN
Center/JJ
for/IN
Allergy/NN
and/CC
Respiratory/JJ
Diseases/NNS
./.
====================
Detailed/JJ
information/NN
on/IN
diet/NN
,/,
smoking/NN
status/NN
,/,
drinking/VBG
status/NN
,/,
lifestyle/JJ
,/,
and/CC
medical/JJ
history/JJ
were/VBD
collected/VBN
by/IN
trained/VBN
interviewers/NNS
using/VBG
a/DT
structured/JJ
questionnaire/RB
./.
====================
Out/CC
of/IN
360/CD
cases/NNS
,/,
information/NN
was/VBD
available/JJ
for/IN
352/CD
on/IN
smoking/NN
status/NN
,/,
317/CD
on/IN
stage/NN
,/,
and/CC
343/CD
on/IN
cell/NN
type/NN
,/,
while/IN
information/NN
was/VBD
available/JJ
for/IN
272/CD
on/IN
smoking/NN
status/NN
of/IN
360/CD
controls/NNS
./.
====================
All/DT
study/NN
subjects/NNS
provided/VBD
written/CD
consent/JJ
and/CC
were/VBD
ethnic/JJ
Koreans/NNS
,/,
and/CC
all/DT
participating/VBG
Institutional/JJ
Review/NN
Boards/NNS
approved/JJ
the/DT
study/NN
protocol/NN
./.
====================
Preparation/NN
of/IN
genomic/JJ
DNA/NN
and/CC
direct/JJ
sequencing/NN
====================
Genomic/JJ
DNA/NN
was/VBD
prepared/VBN
from/IN
peripheral/JJ
blood/NN
samples/NNS
using/VBG
a/DT
Puregene/JJ
blood/NN
DNA/NN
kit/NN
(/(
Gentra/NN
,/,
Minneapolis/NN
,/,
MN/NN
,/,
USA/NN
)/)
,/,
following/VBG
the/DT
manufacturer/NN
's/POS
protocol/NN
./.
====================
To/TO
identify/VB
polymorphisms/NNS
in/IN
the/DT
promoter/NN
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
genes/NNS
,/,
human/JJ
genomic/JJ
DNA/NN
was/VBD
isolated/VBN
from/IN
the/DT
whole/JJ
blood/NN
of/IN
24/CD
lung/NN
cancer/NN
patients/NNS
for/IN
direct/JJ
sequencing/NN
,/,
and/CC
the/DT
promoter/NN
region/NN
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
genes/NNS
was/VBD
amplified/VBN
./.
====================
Polymerase/NN
chain/NN
reaction/NN
(/(
PCR/NN
)/)
amplifications/NNS
were/VBD
performed/VBN
on/IN
a/DT
PTC-225/NN
Peltier/NN
Thermal/JJ
cycler/NN
(/(
MJ/NNP
Research/NN
Inc./NNP
,/,
Waltham/NNP
,/,
MA/NN
,/,
USA/NNP
)/)
using/VBG
Ampli-TagGold/JJ
(/(
Roche/NNP
,/,
Branchburg/NN
,/,
NJ/NNP
,/,
USA/NNP
)/)
./.
====================
All/DT
amplifications/NNS
were/VBD
performed/VBN
using/VBG
35/CD
cycles/NNS
of/IN
30/CD
s/NNS
at/IN
95℃/CD
,/,
1/CD
min/NN
at/IN
64℃/CD
,/,
and/CC
1/CD
min/NN
at/IN
72℃/CD
,/,
followed/VBN
by/IN
a/DT
single/JJ
10-min/NN
extension/NN
at/IN
72℃/CD
./.
====================
PCR/NN
products/NNS
were/VBD
purified/VBN
using/VBG
the/DT
Montage/NN
PCR96/NN
Cleanup/NN
kit/NN
(/(
Millipore/RBR
,/,
Bedford/NN
,/,
MA/NN
,/,
USA/NN
)/)
and/CC
eluted/VBN
in/IN
20/CD
µL/NN
of/IN
nuclease-free/JJ
H2O/NN
./.
====================
DNA/NN
cycle/NN
sequencing/NN
was/VBD
carried/VBN
out/RP
using/VBG
the/DT
BigDye/NN
Terminator/NN
V/JJ
3.1/CD
Cycle/NN
Sequencing/NN
kit/NN
(/(
Perkin/NN
Elmer/NN
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NN
)/)
./.
====================
Multiscreen/JJ
SEQ/NN
384-well/JJ
filter/NN
plates/VBZ
were/VBD
used/VBN
for/IN
dye/NN
removal/NN
,/,
and/CC
sequences/NNS
were/VBD
then/RB
analyzed/VBD
on/IN
an/DT
Applied/VBN
Biosystems/NNS
3700/CD
(/(
ABI/LS
,/,
Foster/NN
City/NN
,/,
CA/NNP
,/,
USA/NNP
)/)
./.
====================
All/DT
polymorphisms/NNS
and/CC
sequence/NN
alignments/NNS
were/VBD
analyzed/VBN
using/VBG
Polyphred/JJ
./.
====================
Genotyping/VBG
====================
After/IN
direct/JJ
sequencing/NN
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
genes/NNS
,/,
we/PRP
performed/VBD
genotyping/VBG
for/IN
the/DT
8/CD
polymorphisms/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
genes/NNS
./.
====================
The/DT
genotypes/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
polymorphisms/NNS
were/VBD
screened/VBN
by/IN
TaqMan/NN
fluorogenic/JJ
5/CD
'/``
nuclease/NN
assay/NN
(/(
ABI/LS
)/)
./.
====================
The/DT
final/JJ
volume/NN
of/IN
the/DT
PCR/NN
was/VBD
5/CD
µL/NN
,/,
containing/VBG
10/CD
ng/NN
of/IN
genomic/JJ
DNA/NN
,/,
and/CC
2.5/CD
µL/NN
TaqMan/NN
Universal/JJ
PCR/NN
Master/NN
Mix/NN
,/,
with/IN
0.13/CD
µL/NN
of/IN
40/CD
×/CD
Assay/NN
Mix/NN
./.
====================
Thermal/JJ
cycle/NN
conditions/NNS
were/VBD
as/IN
follows/VBZ
:/:
50℃/CD
for/IN
2/CD
min/NN
to/TO
activate/VB
uracil/NN
N-glycosylase/NN
and/CC
prevent/VBP
carryover/RB
contamination/NN
,/,
95℃/CD
for/IN
10/CD
min/NN
to/TO
activate/VB
the/DT
DNA/NN
polymerase/NN
,/,
and/CC
45/CD
cycles/NNS
of/IN
95℃/CD
for/IN
15/CD
s/NNS
and/CC
60℃/CD
for/IN
1/CD
min/NN
./.
====================
All/DT
PCRs/NNS
were/VBD
performed/VBN
using/VBG
384-well/JJ
plates/VBZ
on/IN
a/DT
Dual/JJ
384-Well/JJ
GeneAmp/NN
PCR/NN
System/NN
9700/CD
(/(
ABI/LS
)/)
,/,
and/CC
the/DT
endpoint/JJ
fluorescent/JJ
readings/NNS
were/VBD
performed/VBN
on/IN
an/DT
ABI/NN
PRISM/NN
7900/CD
HT/NN
Sequence/NN
Detection/NN
System/NN
(/(
ABI/LS
)/)
./.
====================
Duplicate/IN
samples/NNS
and/CC
negative/JJ
controls/NNS
were/VBD
included/VBN
to/TO
ensure/VB
accuracy/NN
of/IN
genotyping/VBG
./.
====================
Statistical/JJ
analysis/NN
====================
Allele/DT
frequencies/NNS
,/,
genotype/NN
frequencies/NNS
,/,
and/CC
departures/VBZ
of/IN
genotype/NN
distributions/NNS
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NN
)/)
for/IN
each/DT
SNP/NN
were/VBD
analyzed/VBN
using/VBG
chi-square/JJ
test/NN
or/CC
Fisher/RB
's/POS
exact/JJ
test/NN
./.
====================
A/DT
p-value/JJ
of/IN
</JJR
0.05/CD
was/VBD
considered/VBN
statistically/RB
significant/JJ
./.
====================
Linkage/JJ
disequilibrium/NN
(/(
LD/NN
)/)
was/VBD
tested/VBN
on/IN
pairwise/JJ
combinations/NNS
of/IN
polymorphisms/NNS
using/VBG
the/DT
absolute/JJ
value/NN
of/IN
the/DT
standardized/VBN
measure/VB
of/IN
LD/NN
,/,
D/NN
'/``
,/,
calculated/VBN
by/IN
Haploview/NN
version/NN
3.2/CD
./.
====================
The/DT
haplotypes/NNS
and/CC
their/PRP$
frequencies/NNS
were/VBD
estimated/VBN
by/IN
Haploview/NN
version/NN
3.2/CD
./.
====================
Genotype-specific/JJ
risks/NNS
were/VBD
estimated/VBN
as/IN
odds/NNS
ratios/NNS
with/IN
associated/VBN
95/CD
%/NN
confidence/NN
intervals/NNS
by/IN
unconditional/JJ
logistic/JJ
regression/NN
(/(
SAS/NN
Institute/JJ
Inc./NNP
,/,
Cary/NN
,/,
NC/NN
,/,
USA/NNP
)/)
and/CC
adjusted/VBN
for/IN
age/NN
,/,
gender/RB
,/,
and/CC
smoking/NN
status/NN
./.
====================
Table/JJ
1/CD
shows/VBZ
the/DT
clinicopathological/JJ
features/NNS
of/IN
cases/NNS
and/CC
controls/VBZ
./.
====================
All/DT
the/DT
clinical/JJ
characteristics/NNS
,/,
except/IN
for/IN
smoking/NN
status/NN
,/,
were/VBD
not/RB
significantly/RB
different/JJ
between/IN
the/DT
cases/NNS
and/CC
controls/VBZ
./.
====================
This/DT
difference/NN
of/IN
smoking/NN
status/NN
was/VBD
controlled/VBN
in/IN
the/DT
multiple/JJ
logistic/JJ
regression/NN
analysis/NN
,/,
adjusted/VBN
for/IN
age/NN
,/,
gender/NN
,/,
and/CC
smoking/NN
status/NN
./.
====================
By/IN
direct/JJ
sequencing/NN
of/IN
the/DT
AKT2/NN
promoter/NN
region/NN
in/IN
24/CD
lung/NN
cancer/NN
patient/NN
samples/NNS
,/,
we/PRP
identified/VBD
1/CD
novel/JJ
polymorphism/NN
(/(
-9826/CD
C/G/NN
)/)
and/CC
4/CD
known/VBN
polymorphisms/NNS
(/(
-9473/CD
C/T/NN
,/,
-9151/CD
C/T/NN
,/,
-9025/CD
C/T/NN
,/,
and/CC
-8618/CD
G/A/NN
)/)
./.
====================
Also/RB
,/,
we/PRP
identified/VBD
1/CD
novel/JJ
polymorphism/NN
(/(
-811/CD
A/G/NN
)/)
and/CC
2/CD
known/VBN
polymorphisms/NNS
(/(
-675/CD
A/-/JJ
and/CC
-244/CD
C/T/NN
)/)
by/IN
direct/JJ
sequencing/NN
in/IN
the/DT
AKT3/NN
promoter/NN
region/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
genotype/NN
distributions/NNS
of/IN
the/DT
polymorphisms/NNS
were/VBD
in/IN
HWE/NN
./.
====================
Also/RB
,/,
LD/NN
and/CC
haplotypes/NNS
in/IN
the/DT
polymorphisms/NNS
of/IN
AKT2/NN
were/VBD
calculated/VBN
./.
====================
However/RB
,/,
the/DT
LD/NN
and/CC
haplotype/JJ
block/VBP
in/IN
AKT3/NN
polymorphisms/NNS
were/VBD
unidentified/JJ
because/IN
of/IN
the/DT
low/JJ
frequency/NN
of/IN
the/DT
AKT3-811/NN
G/NN
allele/NN
and/CC
AKT3-244/NN
T/NN
allele/NN
(/(
2.1/CD
%/NN
and/CC
2.2/CD
%/NN
,/,
respectively/RB
)/)
(/(
Fig/NN
./.
====================
1/CD
)/)
./.
====================
Accordingly/RB
,/,
we/PRP
focused/VBD
on/IN
the/DT
-675/CD
A/-/JJ
polymorphism/NN
in/IN
the/DT
AKT3/NN
promoter/NN
region/NN
./.
====================
Further/RB
analyses/NNS
were/VBD
then/RB
performed/VBN
on/IN
the/DT
samples/NNS
from/IN
460/CD
lung/NN
cancer/NN
patients/NNS
and/CC
460/CD
controls/NNS
./.
====================
Association/NN
of/IN
lung/NN
cancer/NN
risk/NN
with/IN
AKT/NN
polymorphisms/NNS
was/VBD
then/RB
analyzed/VBD
,/,
revealing/VBG
no/DT
association/NN
of/IN
the/DT
polymorphisms/NNS
with/IN
the/DT
risks/NNS
of/IN
lung/NN
cancer/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
The/DT
association/NN
of/IN
the/DT
polymorphisms/NNS
with/IN
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
was/VBD
further/RBR
examined/VBN
after/IN
stratifying/JJ
the/DT
subjects/NNS
according/VBG
to/TO
gender/VB
and/CC
smoking/NN
status/NN
./.
====================
However/RB
,/,
the/DT
subsequent/JJ
analysis/NN
revealed/VBD
no/DT
significant/JJ
association/NN
./.
====================
Furthermore/RB
,/,
the/DT
haplotypes/NNS
of/IN
the/DT
AKT2/NN
polymorphisms/NNS
were/VBD
not/RB
associated/VBN
with/IN
the/DT
risks/NNS
of/IN
lung/NN
cancer/NN
in/IN
3/CD
alternative/JJ
models/NNS
(/(
data/NNS
not/RB
shown/VBN
)/)
./.
====================
V-akt/RB
murine/JJ
thymoma/NN
viral/JJ
oncogene/NN
homolog/NN
(/(
AKT/NN
)/)
is/VBZ
a/DT
serine/threonine/NN
protein/NN
kinase/NN
that/WDT
is/VBZ
activated/VBN
by/IN
PI3K-α/NN
and/CC
mediates/VBZ
PI3L/NN
signaling/NN
[/(
21/CD
]/)
./.
====================
A/DT
major/JJ
recurrent/JJ
mutation/NN
(/(
Glu17Lys/NNS
)/)
in/IN
the/DT
AKT1/NN
gene/NN
,/,
which/WDT
encodes/VBZ
protein/NN
kinase/NN
B/NN
,/,
has/VBZ
been/VBN
identified/VBN
in/IN
several/JJ
solid/JJ
tumors/NNS
,/,
including/VBG
breast/NN
,/,
colon/NN
,/,
and/CC
ovarian/JJ
cancers/NNS
[/(
22/CD
]/)
./.
====================
Overall/RB
,/,
the/DT
frequency/NN
of/IN
AKT1/NN
mutations/NNS
in/IN
non-small/JJ
cell/NN
lung/NN
carcinoma/NN
(/(
NSCLC/NN
)/)
is/VBZ
about/RB
1/CD
%/NN
,/,
and/CC
they/PRP
have/VBP
only/RB
been/VBN
identified/VBN
in/IN
squamous/JJ
cell/NN
carcinoma/NN
[/(
23/CD
]/)
./.
====================
Also/RB
,/,
mutations/NNS
in/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
genes/NNS
are/VBP
rare/JJ
in/IN
several/JJ
tumors/NNS
,/,
including/VBG
lung/NN
cancer/NN
[/(
15/CD
]/)
./.
====================
Recently/RB
,/,
several/JJ
polymorphisms/NNS
in/IN
the/DT
AKT1/NN
gene/NN
have/VBP
been/VBN
reported/VBN
in/IN
relation/NN
to/TO
human/JJ
disease/NN
[/(
24-26/CD
]/)
./.
====================
Kim/NN
et/FW
al/JJ
./.
====================
[/(
20/CD
]/)
first/JJ
reported/VBD
that/IN
the/DT
AKT1/NN
polymorphisms/NNS
could/MD
be/VB
used/VBN
as/IN
prognostic/JJ
markers/NNS
for/IN
patients/NNS
with/IN
early-stage/JJ
NSCLC/NN
./.
====================
However/RB
,/,
there/EX
has/VBZ
been/VBN
no/DT
study/NN
on/IN
the/DT
association/NN
between/IN
lung/NN
cancer/NN
risk/NN
and/CC
polymorphisms/NNS
of/IN
AKT2/NN
and/CC
AKT3/NN
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
investigated/VBD
the/DT
association/NN
between/IN
AKT2/NN
and/CC
AKT3/NN
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
in/IN
the/DT
Korean/JJ
population/NN
./.
====================
The/DT
genotypes/NNS
and/CC
haplotypes/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
genes/NNS
were/VBD
determined/VBN
in/IN
720/CD
Koreans/NNS
to/TO
evaluate/VB
the/DT
role/NN
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
polymorphisms/NNS
in/IN
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
;/:
however/RB
,/,
the/DT
results/NNS
revealed/VBD
no/DT
significant/JJ
difference/NN
between/IN
lung/NN
cancer/NN
patients/NNS
and/CC
normal/JJ
controls/NNS
./.
====================
Also/RB
,/,
by/IN
TFSEARCH/NN
(/(
version/NN
1.3/CD
)/)
analysis/NN
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
polymorphism/NN
regions/NNS
,/,
the/DT
location/NN
of/IN
these/DT
variants/NNS
did/VBD
not/RB
have/VB
sequences/NNS
for/IN
transcription/NN
factor/NN
binding/NN
sites/NNS
./.
====================
This/DT
result/NN
suggests/VBZ
that/IN
polymorphisms/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
promoter/NN
region/NN
are/VBP
unlikely/JJ
to/TO
play/VB
an/DT
important/JJ
role/NN
in/IN
the/DT
susceptibility/NN
to/TO
lung/NN
cancer/NN
./.
====================
Polymorphisms/NNS
often/RB
show/VBP
ethnic/JJ
variation/NN
[/(
6/CD
,/,
27/CD
]/)
./.
====================
In/IN
the/DT
present/JJ
study/NN
,/,
we/PRP
observed/VBD
the/DT
frequencies/NNS
of/IN
5/CD
polymorphisms/NNS
in/IN
the/DT
AKT2/NN
promoter/NN
region/NN
,/,
and/CC
we/PRP
observed/VBD
frequencies/NNS
of/IN
3/CD
polymorphisms/NNS
in/IN
the/DT
AKT3/NN
promoter/NN
region/NN
in/IN
24/CD
Korean/NN
populations/NNS
using/VBG
direct/JJ
sequencing/NN
./.
====================
In/IN
the/DT
direct/JJ
sequencing/NN
result/NN
,/,
we/PRP
detected/VBD
no/DT
frequencies/NNS
in/IN
another/DT
known/JJ
polymorphisms/NNS
(/(
AKT2/NN
:/:
rs11666690/CD
,/,
rs11665880/CD
,/,
rs35814223/NN
,/,
rs34408497/NN
,/,
rs35408040/CD
,/,
rs10418387/NN
;/:
AKT3/NN
:/:
rs11588441/NN
,/,
rs6679386/NN
,/,
rs41267521/NN
)/)
./.
====================
The/DT
frequencies/NNS
of/IN
AKT2/NN
promoter/NN
polymorphisms/NNS
showed/VBD
similar/JJ
frequencies/NNS
in/IN
the/DT
Asian/JJ
ethnic/JJ
groups/NNS
(/(
Han/JJ
Chinese/JJ
and/CC
Japanese/JJ
)/)
of/IN
the/DT
dbSNP/NN
database/NN
(/(
www.ncbi.nlm.nih.gov/SNP/NN
)/)
./.
====================
The/DT
frequency/NN
of/IN
the/DT
minor/JJ
allele/NN
of/IN
rs35835614/NN
in/IN
the/DT
AKT3/NN
gene/NN
was/VBD
0.275/CD
;/:
however/RB
,/,
the/DT
frequency/NN
of/IN
this/DT
polymorphism/NN
has/VBZ
not/RB
been/VBN
reported/VBN
in/IN
the/DT
dbSNP/NN
database/NN
(/(
www.ncbi.nlm.nih.gov/SNP/NN
)/)
./.
====================
A/DT
series/NN
of/IN
our/PRP$
previous/JJ
studies/NNS
showed/VBD
that/IN
polymorphisms/NNS
of/IN
oncogenes/NNS
,/,
tumor/NN
suppressor/NN
genes/NNS
,/,
and/CC
receptor/NN
tyrosine/NN
kinases/NNS
are/VBP
related/JJ
to/TO
lung/NN
cancer/NN
risk/NN
[/(
6/CD
,/,
28/CD
,/,
29/CD
]/)
./.
====================
Recently/RB
,/,
we/PRP
reported/VBD
that/IN
STK11/NN
and/CC
PIK3CA/NN
polymorphisms/NNS
are/VBP
not/RB
related/JJ
to/TO
genetic/JJ
susceptibility/NN
to/TO
lung/NN
cancer/NN
[/(
30/CD
,/,
31/CD
]/)
./.
====================
The/DT
genotypes/NNS
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
promoter/NN
polymorphisms/NNS
,/,
determined/VBN
in/IN
720/CD
Koreans/NNS
in/IN
the/DT
present/JJ
study/NN
,/,
revealed/VBD
no/DT
significant/JJ
difference/NN
between/IN
lung/NN
cancer/NN
patients/NNS
and/CC
normal/JJ
controls/NNS
./.
====================
To/TO
our/PRP$
best/JJS
knowledge/NN
,/,
this/DT
is/VBZ
the/DT
first/JJ
study/NN
on/IN
the/DT
association/NN
of/IN
AKT2/NN
and/CC
AKT3/NN
promoter/NN
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
in/IN
a/DT
Korean/JJ
population/NN
./.
====================
Polymorphism/NN
location/NN
in/IN
promoter/NN
region/NN
and/CC
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
./.
====================
Coding/VBG
exons/NNS
are/VBP
marked/JJ
by/IN
black/JJ
blocks/VBZ
,/,
and/CC
untranslated/JJ
regions/NNS
are/VBP
marked/JJ
by/IN
white/JJ
blocks/VBZ
./.
====================
The/DT
first/JJ
base/NN
of/IN
the/DT
translational/JJ
site/NN
is/VBZ
denoted/VBN
as/IN
nucleotide/JJ
+1/CD
./.
====================
(/(
A/NN
)/)
AKT2/NN
location/NN
of/IN
promoter/NN
polymorphisms/NNS
and/CC
LD/NN
block/VBP
./.
====================
(/(
B/NN
)/)
AKT3/NN
location/NN
of/IN
promoter/NN
polymorphisms/NNS
./.
====================
The/DT
LD/NN
of/IN
AKT3/NN
polymorphisms/NNS
was/VBD
not/RB
identified/VBN
./.
====================
aFurther/DT
analyses/NNS
polymorphism/NN
sites/NNS
./.
====================
Characteristics/NNS
of/IN
the/DT
study/NN
subjects/NNS
====================
Polymorphism/NN
confirmation/NN
of/IN
the/DT
AKT2/NN
and/CC
AKT3/NN
promoter/NN
region/NN
by/IN
direct/JJ
sequencing/NN
====================
Association/NN
between/IN
AKT2/NN
and/CC
AKT3/NN
promoter/NN
polymorphisms/NNS
and/CC
the/DT
risk/NN
of/IN
lung/NN
cancer/NN
====================
